News

WALTHAM, Mass., May 24, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.

"These presentations at ASCO will include the first clinical data for our IMGN388 compound for solid tumors, and also the first data for a TAP compound used in a combination regimen," commented Daniel Junius, President and CEO. "Our clinical pipeline not only continues to grow through progress with additional TAP compounds, but also to mature through an increase in planned and ongoing advanced clinical trials."

TAP-Related Presentations and Discussions at ASCO

Abstract #1012: A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for women with HER2-positive, locally advanced or metastatic breast cancer who were previously treated with trastuzumab

• Poster presentation: Saturday, June 5, 8:00 am - 12:00 noon in E450b
• Poster discussion session: Saturday, June 5, 12:00 noon - 1:00 pm in E Hall D1

Abstract #1016: Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients with metastatic breast cancer who had progressed on prior HER2-directed therapy

• Poster presentation: Saturday, June 5, 8:00 am - 12:00 noon in E450b
• Poster discussion session: Saturday, June 5, 12:00 noon - 1:00 pm in E Hall D1

Abstract #3058: A phase I dose-escalation study of IMGN388 in patients with solid tumors

• Poster presentation: Monday, June 7, 8:00 am - 12:00 noon in S Hall A2

Additionally, John Lambert, Ph.D., Executive Vice President and Chief Scientific Officer of ImmunoGen, will be participating on the panel, "New Targeted Therapies for Resistant Cancers" being held on Monday, June 7, in conjunction with ASCO.

About ImmunoGen's Targeted Antibody Payload (TAP) Technology

The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents (e.g., DM1, DM4) specifically to tumors. ImmunoGen developed these agents specifically for targeted delivery to tumor cells. They are many-fold more potent than standard chemotherapeutics and are designed to be attached to antibodies using one of the Company's engineered linkers. In addition to T-DM1 and IMGN388, four other compounds that make use of ImmunoGen's TAP technology are in clinical testing.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumors. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer Schering Pharma and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including T-DM1 and IMGN388, including risks related to uncertainties around clinical trials conducted and their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and other reports filed with the Securities and Exchange Commission.

SOURCE: ImmunoGen

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Adriana Jenkins, 617-744-1713